The American Psychiatric Association Practice Guideline for                     the Pharmacological Treatment of Patients With Alcohol Use                     Disorder

doi:10.1176/appi.books.9781615371969

Cited by 6 publications

(5 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The American Society of Addiction Medicine and American Psychiatric Association suggest the use of alcohol biomarkers as an aid to diagnosis, to support recovery, and as catalysts for discussion with the patient, rather than as tools to "catch" or punish patients. (36,37) Principles of use include discussing biomarker use with patients before testing, to maintain therapeutic alliance and improve alcohol use disclosure. Each of the alcohol biomarkers described subsequently has limitations.…”

Section: Biomarkers Of Alcohol Usementioning

confidence: 99%

Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases

et al. 2020

View full text Add to dashboard Cite

Section: Biomarkers Of Alcohol Usementioning

confidence: 99%

Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases

et al. 2020

View full text Add to dashboard Cite

“…[12][13][14][15][16][17] Noting the high societal and personal burdens associated with AUD and the high rate of undertreatment, the American Psychiatric Association released a new practice guideline to inform the prescribing of AUD medications in 2018. 18 Little is currently known about how AUD medications are being used among commercially insured individuals or factors associated with AUD medication use earlier in the course of illness. One analysis of 2014-2015 Cigna data found that 6.2-7.6% of enrollees diagnosed with AUD filled an AUD medication prescription each year, although the study did not identify predictors of AUD medication fills.…”

mentioning

confidence: 99%

Medication Utilization for Alcohol Use Disorder in a Commercially Insured Population

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The 2018 American Psychiatric Association guidelines stated that gabapentin had a small positive effect on drinking outcomes, but the harm of treatment was deemed minimal, especially relative to the harms of chronic drinking. 33 The guidelines endorse the use of gabapentin in patients with moderate to severe AUD who select gabapentin from the available options, or for those who are nonresponsive to or cannot tolerate naltrexone or acamprosate, as long as no contraindications exist. It was also noted that even small effects may be clinically important, considering the signifi cant morbidity associated with AUD.…”

Section: Bottom Line: Evidence Of Benefi Ts Mixed But Risk Lowmentioning

confidence: 99%

Gabapentin for alcohol use disorder: A good option, or cause for concern?

Modesto‐Lowe

Barron

Aronow

et al. 2019

CCJM

View full text Add to dashboard Cite

P erceptions regarding the use of gabapentin for alcohol use disorder (AUD) have shifted over time. 1-4 Early on, the drug was deemed to be benign and effective. 4-6 But more and more, concerns are being raised about its recreational use to achieve euphoria, 7 and the drug is often misused by vulnerable populations, particularly those with opioid use disorder. 7-9 Given the large number of gabapentin prescriptions written off-label for AUD, it is incumbent on providers to understand how to prescribe it responsibly. 7-9 To that end, this article focuses on the benefi tsand concerns-of this treatment option. We describe the effects of gabapentin on the central nervous system and how it may mitigate alcohol withdrawal and increase the likelihood of abstinence. In addition, we review clinical trials that evaluated potential roles of gabapentin in AUD, discuss the drug's misuse potential, and suggest a framework for its appropriate use in AUD management. ■ ALCOHOL USE DISORDER IS COMMON AND SERIOUS AUD affects about 14% of US adults and represents a signifi cant health burden, 1 often with severe clinical and social implications. It manifests as compulsive drinking and loss of control despite adverse consequences on various life domains. 10 It is generally associated with cravings, tolerance, and withdrawal symptoms upon cessation. Alcohol withdrawal is characterized by tremors, anxiety, sweating, nausea, and tachycardia, and in severe cases, may involve hallucinations, seizures, and delirium tremens. Untreated, alcohol withdrawal can be fatal. 10

show abstract

The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder

Cited by 6 publications

References 139 publications

Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases

Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases

Medication Utilization for Alcohol Use Disorder in a Commercially Insured Population

Gabapentin for alcohol use disorder: A good option, or cause for concern?

Contact Info

Product

Resources

About